Vaxcyte (PCVX) Accounts Payables (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Accounts Payables data on file, last reported at $63.1 million in Q1 2026.

• Accounts Payables for Q1 2026 came in at $63.1 million, up 207.4% year-over-year; the trailing twelve-month figure through Mar 2026 was $63.1 million (up 207.4% YoY), and the FY2025 annual result was $70.9 million, up 46.34% from the prior year.
• Accounts Payables declined to $63.1 million in Q1 2026 per PCVX's latest filing, from $70.9 million in the prior quarter.
• Over five years, Accounts Payables peaked at $70.9 million in Q4 2025 and troughed at $4.8 million in Q1 2022.
• A 5-year average of $24.6 million and a median of $16.3 million in 2023 frame the typical range for Accounts Payables.
• The sharpest annual moves came in 2022 and 2024: Accounts Payables tumbled 84.93% in 2022, then jumped 232.16% in 2024.
• A 5-year view of Accounts Payables shows it stood at $9.8 million in 2022, then jumped by 48.92% to $14.6 million in 2023, then jumped by 232.16% to $48.5 million in 2024, then soared by 46.34% to $70.9 million in 2025, then declined by 11.06% to $63.1 million in 2026.
• Business Quant data shows PCVX's Accounts Payables at $63.1 million in Q1 2026, $70.9 million in Q4 2025, and $49.0 million in Q3 2025.